Home/Filings/4/0001209191-23-005588
4//SEC Filing

Freeman Mason 4

Accession 0001209191-23-005588

CIK 0001868734other

Filed

Jan 29, 7:00 PM ET

Accepted

Jan 30, 8:03 PM ET

Size

6.4 KB

Accession

0001209191-23-005588

Insider Transaction Report

Form 4
Period: 2023-01-26
Freeman Mason
EVP Clinical Development
Transactions
  • Award

    Common Stock

    2023-01-26+40,00042,500 total
Holdings
  • Common Stock

    (indirect: By Spouse)
    100
Footnotes (2)
  • [F1]Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-fourth (1/4) of the RSUs shall vest on January 26, 2024 and the remaining RSUs shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continuous service through each such vesting date; provided that, in the event the previously announced pending acquisition of the Issuer by AstraZeneca PLC occurs, 50% of the RSUs shall vest immediately prior to the closing of such transaction, subject to the Reporting Person's continuous service through such date, and the remaining 50% of the RSUs shall be cancelled as of such date.
  • [F2]The securities are held by the Reporting Person's spouse. The Reporting Person shares voting and investment control of the shares and may be deemed to beneficially own the shares. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his proportionate pecuniary interest therein.

Issuer

CinCor Pharma, Inc.

CIK 0001868734

Entity typeother

Related Parties

1
  • filerCIK 0001745948

Filing Metadata

Form type
4
Filed
Jan 29, 7:00 PM ET
Accepted
Jan 30, 8:03 PM ET
Size
6.4 KB